Rxo (RXO) Cash & Equivalents (2021 - 2026)

Rxo (RXO) has reported Cash & Equivalents for 6 consecutive years, with $21.0 million the latest figure, recorded in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $21.0 million, up 31.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.0 million (up 31.25% YoY), and the FY2025 annual result was $17.0 million, down 51.43% from the prior year.
• Cash & Equivalents was $21.0 million for Q1 2026 at Rxo, up from $17.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $187.0 million in Q3 2022 and troughed at $5.0 million in Q4 2023.
• Average Cash & Equivalents over 5 years is $56.0 million, with a median of $25.0 million recorded in 2025.
• Year-over-year, Cash & Equivalents tumbled 94.9% in 2023 and jumped 600.0% in 2024.
• Over 5 years, Cash & Equivalents stood at $98.0 million in 2022, then sank by 94.9% to $5.0 million in 2023, then surged by 600.0% to $35.0 million in 2024, then sank by 51.43% to $17.0 million in 2025, then gained by 23.53% to $21.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $21.0 million in Q1 2026, $17.0 million in Q4 2025, and $25.0 million in Q3 2025.